News stories about Pacific Biosciences of California (NASDAQ:PACB) have been trending positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a daily sentiment score of 0.35 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.7030122233891 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
A number of research firms have weighed in on PACB. First Analysis cut shares of Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 price objective for the company. in a report on Friday, November 3rd. Zacks Investment Research cut shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, BidaskClub raised shares of Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a report on Thursday, December 21st. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Pacific Biosciences of California currently has an average rating of “Hold” and a consensus price target of $6.27.
Pacific Biosciences of California (NASDAQ PACB) opened at $2.57 on Friday. Pacific Biosciences of California has a fifty-two week low of $2.21 and a fifty-two week high of $5.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.75 and a quick ratio of 3.15. The firm has a market cap of $327.00, a price-to-earnings ratio of -2.89 and a beta of 1.41.
Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings data on Thursday, February 1st. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Pacific Biosciences of California had a negative net margin of 98.63% and a negative return on equity of 96.55%. The company had revenue of $24.94 million during the quarter, compared to analysts’ expectations of $21.89 million. During the same quarter in the previous year, the company earned ($0.21) earnings per share. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. equities research analysts expect that Pacific Biosciences of California will post -0.68 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/17/favorable-news-coverage-somewhat-unlikely-to-affect-pacific-biosciences-of-california-pacb-share-price.html.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.